Abstract

IntroductionHyperlactatemia represents one prominent component of the metabolic response to sepsis. In critically ill patients, hyperlactatemia is related to the severity of the underlying condition. Both an increased production and a decreased utilization and clearance might be involved in this process, but their relative contribution remains unknown. The present study aimed at assessing systemic and muscle lactate production and systemic lactate clearance in healthy human volunteers, using intravenous endotoxin (LPS) challenge.MethodsFourteen healthy male volunteers were enrolled in 2 consecutive studies (n = 6 in trial 1 and n = 8 in trial 2). Each subject took part in one of two investigation days (LPS-day with endotoxin injection and placebo-day with saline injection) separated by one week at least and in a random order. In trial 1, their muscle lactate metabolism was monitored using microdialysis. In trial 2, their systemic lactate metabolism was monitored by means of a constant infusion of exogenous lactate. Energy metabolism was monitored by indirect calorimetry and glucose kinetics was measured with 6,6-H2 glucose.ResultsIn both trials, LPS increased energy expenditure (p = 0.011), lipid oxidation (p<0.0001), and plasma lactate concentration (p = 0.016). In trial 1, lactate concentration in the muscle microdialysate was higher than in blood, indicating lactate production by muscles. This was, however, similar with and without LPS. In trial 2, calculated systemic lactate production increased after LPS (p = 0.031), while lactate clearance remained unchanged.ConclusionsLPS administration increases lactatemia by increasing lactate production rather than by decreasing lactate clearance. Muscle is, however, unlikely to be a major contributor to this increase in lactate production.Trial registrationClinicalTrials.gov NCT01647997

Highlights

  • Hyperlactatemia represents one prominent component of the metabolic response to sepsis

  • In trial 2, calculated systemic lactate production increased after LPS (p = 0.031), while lactate clearance remained unchanged

  • Unlikely to be a major contributor to this increase in lactate production

Read more

Summary

Introduction

Hyperlactatemia represents one prominent component of the metabolic response to sepsis. Hyperlactatemia is related to the severity of the underlying condition. Both an increased production and a decreased utilization and clearance might be involved in this process, but their relative contribution remains unknown. Sepsis and inflammation elicit a whole set of neuroendocrine, metabolic, and systemic responses that belong to the organism’s defense mechanisms [1,2]. When excessive, these responses may exert deleterious effects [3]. The mechanisms underlying the development of hyperlactatemia in sepsis remain poorly understood: increased production or decreased clearance or a combination of both are possible [8]. The relative importance of these two processes, as well as the major tissues where lactate metabolism is altered by sepsis, remains incompletely understood

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.